February 2023 in “European Journal of Dermatology” In this retrospective study from North France, apremilast was used in patients with psoriasis and recent cancer, showing a good safety profile and improved quality of life, though with 65.2% experiencing non-serious adverse events. The need for further research on oncological safety was highlighted.
August 2024 in “Quality in Sport” This review article examines the latest understanding of androgenetic alopecia's causes and treatment options, emphasizing current research on alternative treatments beyond the approved medications, finasteride and minoxidil, due to potential side effects and the psychological impact of the condition.
June 2025 in “Australian Prescriber” In this study, the authors highlighted treatments for androgenetic alopecia, noting that combination therapies with drugs like minoxidil and antiandrogens often require at least 6 months for clinical improvement, while also emphasizing the value of patient counseling for informed treatment choices.
1 citations
,
July 2023 in “Journal of Clinical Medicine” This review provides a detailed overview of the causes, prevalence, pathophysiology, clinical presentation, and treatment of beard alopecia, highlighting conditions such as alopecia areata, pseudofolliculitis barbae, and tinea barbae, and aims to serve as a resource for clinicians handling such cases.
October 2025 in “Nature Reviews Disease Primers”